linjc16/ctgov huggingface dataset:
Losartan Therapy in Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.

Official Title
-----------------
Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: nifedipine, losartan
* Drug: losartan
* Drug: Nifedipine, losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean pulmonary artery pressure of > 26mmHg) Exclusion Criteria: acute infectious or inflammatory disease, exacerbation of chronic obstructive pulmonary disease, malignancy, acute coronary syndrome in the last 4 weeks, uncontrolled arrhythmia and hypertension, decompensated heart failure, acute pulmonary emboli, thrombus in a lower extremity, oxygen saturation below 85% at rest, failure to cooperate with CPET
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: I, II<br>I: nifedipine II: losartan | Drug: nifedipine, losartan<br>* I: nifedipine 30 mg/d II: losartan 50 mg/d<br>* Other names: losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA);Drug: losartan<br>* II: losartan<br>* Other names: losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA) 50 mg/d;Drug: Nifedipine, losartan<br>* I: nifedipine II: losartan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary hypertension, Angiotensin receptor blocker, Calcium channel blocker
Is There a Relationship Between the Risk of Injury and Posture in Wrestlers?

Study Overview
=================
Brief Summary
-----------------
This study was planned to investigate the relationship between the risk of injury and posture in wrestlers. The study will be included male wrestlers. The spine posture and flexibility of the athletes will be measured during standing position with the Idiag M360® brand Spinal Mouse (SM), while the overall body posture will be measured from the anterior and lateral sides using the New York Posture Analysis Method (NYPAM). Injury risks of the athletes will be evaluated by Functional Movement Screen (FMS) which was consisting of seven basic movement patterns.

Official Title
-----------------
Is There a Relationship Between the Risk of Injury and Posture in Wrestlers?

Conditions
-----------------
Posture, Sport Injury, Wrestling, Risk Reduction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being between the ages of 18 and 40 To be a professional wrestler who won medals in the Turkey championships Exclusion Criteria: had injury for in the last 6 months had a history of surgery, or chronic and progressive disease had any orthopaedic or neurological problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Posture Assessment<br>Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958 | |
| Sagittal spinal alignment and mobility<br>Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device. | |
| Injury risk assessment<br>Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posture Assessment | Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958 | 2 weeks | 
| Sagittal spinal alignment and mobility | Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device | 2 weeks | 
| Injury risk assessment | Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wrestling, Functional movement screen, Injury risk, Posture
Influence of Gum Disease Treatment on Long-term Dental Implant Success

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the influence of periodontal care response on long term dental implant success. Investigator's hypothesis is that patients who do not well respond to periodontal care have more chance to develop peri-implant complications at long-term. The second purpose of this study is to evaluate the influence of other local, systemic, behavioral, and implant's related risk factors

Official Title
-----------------
Influence of Periodontal Care Response on Implant Treatment Outcomes at Long-term

Conditions
-----------------
Periodontitis

Intervention / Treatment
-----------------
* Procedure: PARORISKIMPLANT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient attending supporting periodontal therapy with at least one implant placed for more than 3 years Patient with more than 12 teeth at baseline Patient with demographic, periodontal, implant data recording patient aged >30 years at Baseline Exclusion criteria: Patient needed antibiotic prophylaxis Uncontrolled diabetes Systemic inflammatory or autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of peri-implantitis as measured by probing depth | The implant has a probing depth more than or equal to 4 mm | At least 3 years after dental implant placement | 
| Presence of peri-implantitis as measured by erythema | The implant has bleeding on probing | At least 3 years after dental implant placement | 
| Presence of peri-implantitis as measured by radiographic bone loss | The implant has a radiographic bone loss when compared to previous radiographs | At least 3 years after dental implant placement | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant survival | presence of implant on arch Peri-implant mucositis: presence of bleeding on probing | At least 3 years after dental implant placement |
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.

Official Title
-----------------
Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)

Conditions
-----------------
Hyperphosphatemia

Intervention / Treatment
-----------------
* Drug: Lanthanum Carbonate (BAY77-1931)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Serum phosphate levels: >5.0 mg/dL and <11.0 mg/dL 2 weeks after the initiation of the washout period Out-patient Undergoing CAPD for at least previous 3 consecutive months Exclusion Criteria: Who may not enable to continue CAPD Serum phosphate levels of >=10.0 mg/dL at the start of the washout period or >=11.0 mg/dL 2 week after Corrected serum calcium level of <7.0 mg/dL at the start of the washout period or >=11.0 mg/dL 2 week after Serum intact PTH (Parathyroid) of >=1000 pg/mL at the start of the washout period Pregnant woman, or lactating mother Significant gastrointestinal disorders including known acute peptic ulcer Liver dysfunction History of cardiovascular or cerebrovascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>750-2250mg/day, tid, 8 weeks | Drug: Lanthanum Carbonate (BAY77-1931)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in serum phosphate levels at the end of the treatment period |  | Baseline to Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants achieving the target PSPL (Pre-dialysis serum phosphate level) and time to achievement |  | Week 8 | 
| Serum calcium level corrected by serum albumin level at the end of the treatment period |  | Week 8 | 
| Serum calcium x phosphate product at the end of the treatment period |  | Week 8 | 
| Serum intact-PTH (Parathyroid) levels at the end of the treatment period |  | Week 8 | 
| Safety variables will be summarized using descriptive statistics based on adverse events collection |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Study Overview
=================
Brief Summary
-----------------
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.

Official Title
-----------------
PhaseII, Randomized, Double-blind, Placebo Controlled, Multi-center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Glabellar Lines

Conditions
-----------------
Glabellar Frown Lines

Intervention / Treatment
-----------------
* Drug: MBA-P01 (Botulinum toxin A)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female over 18 years of age Bilaterally symmetrical moderate to severe GL at maximum frown as assessed by both investigator and subject using FWS Exclusion Criteria: History of facial nerve paralysis Any eyebrow or eyelied ptosis as determined by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MBA-P01 30U<br>Experimental group, Dose: 30U | Drug: MBA-P01 (Botulinum toxin A)<br>* Intramuscular injection, dose varies by groups<br>|
| Experimental: MBA-P01 20U<br>Experimental group, Dose: 20U | Drug: MBA-P01 (Botulinum toxin A)<br>* Intramuscular injection, dose varies by groups<br>|
| Experimental: MBA-P01 10U<br>Experimental group, Dose: 10U | Drug: MBA-P01 (Botulinum toxin A)<br>* Intramuscular injection, dose varies by groups<br>|
| Placebo Comparator: Placebo<br>Placebo group, Normal saline | Drug: Placebo<br>* Intramuscular injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Facial Wrinkle Scale(FWS) change | Proportion of subjects achieving at least a 2-grade decrease from baseline in score of Facial Wrinkle Scale (FWS) (0:none to 3: severe) of Glabellar line at maximum frown | 4 weeks |
REFLECTION: A Clinical Practice Learning Program for Galleri®

Study Overview
=================
Brief Summary
-----------------
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.

Official Title
-----------------
REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri®

Conditions
-----------------
Early Detection of Cancer, Cancer

Intervention / Treatment
-----------------
* Other: MCED
* Other: SOC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: Participant has the ability to understand and the willingness to sign a written informed consent form (ICF); Participant is at least 22 years old at the time of consent; A provider or their designee has ordered the Galleri® test; and Participant has the ability to comprehend the participant questionnaires. Exclusion Criteria: There are no exclusions

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients who received the Galleri® test.<br> | Other: MCED<br>* Multi-cancer early detection (MCED) test<br>Other: SOC<br>* Standard of care cancer screening<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting. |  | Up to 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Galleri®: To assess the feasibility and acceptability of Galleri® from the perspective of participants and patient-reported outcomes (PROs) in a real-world setting. |  | Up to 12 Months | 
| HCRU: To assess healthcare resource utilization (HCRU) associated with cancer diagnostic workups for participants with signal detected Galleri® test results. |  | Up to 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multi-cancer early detection, Cancer screening, Circulating cell-free tumor DNA
Prediction of Sepsis After Flexible Ureteroscopy

Study Overview
=================
Brief Summary
-----------------
Sepsis is a lethal complication of flexible ureteroscopy. The aim of this study is to identify predictors of sepsis after flexible ureteroscopy in patients with solitary proximal ureteral stones.

Official Title
-----------------
Prediction of Sepsis After Flexible Ureteroscopy in Patients With Proximal Ureteral Stone by Using Preoperative Factors

Conditions
-----------------
Urolithiasis, Sepsis, Surgery--Complications

Intervention / Treatment
-----------------
* Procedure: flexible ureteroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of fURS to treat unilateral, solitary, and proximal ureteral stones age ≥18 years Exclusion Criteria: anatomical renal abnormalities such as transplant kidney, solitary kidney, horseshoe kidney, and kidney duplication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| proximal ureteral stone patient<br> | Procedure: flexible ureteroscopy<br>* flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication-sepsis | sepsis is defined as the concurrence of infection and at least 2 of the following 4 criteria: (1) body temperature >38°C, (2) heart rate >90/minute, (3) respiratory rate >20/minute, and (4) leukocyte count <4,000 cells/μL or >12,000 cells/μL | within 48 hour after surgery |
Can the Point-Of-Care Chemistry Test (POCT) Solve the Emergency Department (ED) Crowding?

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study that the Point-Of-Care Chemistry Test (POCT) may shorten Emergency Department (ED) length of stay (LOS).

Detailed Description
-----------------
ED crowding is one of the most serious problems in ED. POCT has shorter turn-around time compared to centralized laboratory system. If POCT introduce to ED, it may help to shorten LOS of ED patients.

Official Title
-----------------
A Randomized Controlled Trial Comparing Central Laboratory and Point-of-care Chemistry Test for Solving the Emergency Department Crowding

Conditions
-----------------
Crowding

Intervention / Treatment
-----------------
* Device: point-of-care chemistry test(POCT) (Piccolo)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 15 years clinically required to have chemistry lab tests ESI 2-5 written agreement to participate Exclusion Criteria: no agreement ESI level 1 no chemistry lab

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: POCT lab<br>The patient group whose laboratory test perform by POCT chemistry analyzer. | Device: point-of-care chemistry test(POCT) (Piccolo)<br>* comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.<br>* Other names: Piccolo® Comprehensive Metabolic Reagent Disc;|
| Active Comparator: central laboratory group(CLT)<br>The patients group whose laboratory test perform by central laboratory. | Device: point-of-care chemistry test(POCT) (Piccolo)<br>* comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.<br>* Other names: Piccolo® Comprehensive Metabolic Reagent Disc;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay | Time interval between registration at ED and leaving at ED(discharge, admission, etc.) | average 7days from ED visit(up to time of discharge at ED or admission to ward) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay(subgroup) | length of stay analysis for Emergency Severity Index (ESI) 3-4, admission or discharge group | average 7days from ED visit (up to time of discharge at ED or admission to ward) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
crowding, Point-of-Care Systems, emergency medicine